Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research report issued on Thursday. The brokerage set a “buy” rating on the biotechnology company’s stock.

A number of other equities analysts also recently weighed in on ADAP. Guggenheim decreased their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, November 15th. HC Wainwright dropped their target price on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Thursday, November 14th. Finally, Mizuho reduced their price target on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a report on Wednesday, November 27th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $2.79.

Adaptimmune Therapeutics Trading Up 0.5 %

NASDAQ ADAP opened at $0.45 on Thursday. The stock’s 50 day moving average is $0.57 and its 200 day moving average is $0.73. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $115.22 million, a PE ratio of -2.05 and a beta of 2.52. Adaptimmune Therapeutics has a twelve month low of $0.44 and a twelve month high of $1.65.

Hedge Funds Weigh In On Adaptimmune Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ADAP. Invesco Ltd. raised its holdings in Adaptimmune Therapeutics by 82.0% in the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 28,526 shares during the last quarter. Two Sigma Advisers LP raised its holdings in Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 58,787 shares during the last quarter. Two Sigma Investments LP raised its holdings in Adaptimmune Therapeutics by 33.5% in the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 19,146 shares during the last quarter. Virtu Financial LLC raised its holdings in Adaptimmune Therapeutics by 21.5% in the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 21,688 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Adaptimmune Therapeutics in the 3rd quarter worth approximately $95,000. 31.37% of the stock is currently owned by hedge funds and other institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.